Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05662345 · ClinicalTrials.gov registry record
ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
A clinical trial of Metastatic Breast Cancer, sponsored by Menarini Silicon Biosystems.
- Active
- Registry status
- 65
- Enrollment target
- 4
- Study locations
NCT05662345 is a study of Metastatic Breast Cancer that is active but no longer recruiting, run by Menarini Silicon Biosystems. The registered enrollment target is 65 participants, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (68% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT05662345, a study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Menarini Silicon Biosystems.
- ACTIVE NOT RECRUITING
- Registry status
- 65 participants
- Enrollment target
- 4
- Study locations
Study Summary
ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST CellSearch Circulating Tumor Cells
Study Locations (4)
Minnesota
- Mayo Clinic Health System Albert Lea - Albert Lea
- Mayo Clinic Health System Mankato - Mankato
- Mayo Clinic - Rochester
Wisconsin
- MCHS Eau Claire - Eau Claire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2026-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05662345
The ClinicalTrials.gov registry entry for NCT05662345 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 205-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Menarini Silicon Biosystems, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CellSearch Circulating Tumor Cells is the first listed.
NCT05662345 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05662345 about?
NCT05662345 is a clinical study titled "ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)". ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.
What is the current status of trial NCT05662345?
This trial is currently active not recruiting. The enrollment target is 65 participants. The study started on 2022-12-12. Estimated completion is 2026-10.
What conditions does trial NCT05662345 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05662345?
The interventions under investigation include: CellSearch Circulating Tumor Cells (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05662345?
This trial is sponsored by Menarini Silicon Biosystems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05662345 being conducted?
This trial has 4 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.